Regulation FD Disclosure

Business Context and Reporting Period

This Form 8-K, dated April 24, 2026, is filed by Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP). The report announces the completion of a business combination with Z Squared Inc. Following this transaction, the combined entity's public shares are scheduled to commence trading on the Nasdaq Global Market under the new ticker symbol "ZSQR" on April 27, 2026.

Key Financial Metrics

The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report serves as a notification of a corporate event rather than a financial performance statement.

Material Changes

  • Corporate Structure: Completion of the business combination between Coeptis Therapeutics Holdings, Inc. and Z Squared Inc.
  • Trading Status: Transition from the Nasdaq Capital Market (COEP) to the Nasdaq Global Market (ZSQR).
  • Security Identification: New CUSIP assigned: 98878K108.

Guidance, Outlook, and Risks

The filing references a press release (Exhibit 99.1) for further details but does not contain specific management commentary, financial guidance, or risk factors within the text provided. The document explicitly states that the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Verify the commencement of trading for the new ticker symbol "ZSQR" on April 27, 2026.
  • Confirm the new CUSIP number (98878K108) for the combined entity.
  • Review the full text of the press release (Exhibit 99.1) for details on the transaction terms and post-merger capital structure.
  • Check for any subsequent filings regarding the delisting of the former COEP and COEPW securities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.